Physician
ST. Luke's Hospital Monroe Campus
ST. Luke's Hospital Monroe Campus was paid $11.88M by Medicaid between Jan 2018 and Dec 2024, across 199 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoST. LUKE'S HOSPITAL MONROE CAMPUS
STROUDSBURG, PA 18360
STROUDSBURG, PA 18360
33aNPI1396194197assigned 06/13/2016
33bProvider typeEmergency Medicine Physician
28Total paid$11.88M
24GClaims273,201
24DCodes billed199
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Pennsylvania
Rank by total paid#6 of 1,211
Median peer was paid$19K
This provider vs. median610×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WOLFE, SCOTT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 413 | $56K | |
| 2019 | 3,741 | $288K | |
| 2020 | 26,108 | $1.18M | |
| 2021 | 90,663 | $3.66M | |
| 2022 | 47,251 | $2.14M | |
| 2023 | 60,705 | $2.66M | |
| 2024incomplete | 44,320 | $1.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 25,749 | 24,853 | $2.42M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 18,949 | 18,172 | $2.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 7,255 | 6,905 | $1.20M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.0% | 11,795 | 11,188 | $951K |
| G0378 | Hospital observation service, per hour | 5.8% | 763 | 669 | $695K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 4.8% | 15,217 | 4,193 | $574K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 2,969 | 2,878 | $536K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.3% | 4,704 | 4,592 | $506K |
| 80053 | Comprehensive metabolic panel | 1.6% | 18,553 | 17,553 | $193K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 3,158 | 3,033 | $171K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 932 | 893 | $155K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 1.3% | 1,380 | 1,380 | $153K |
187 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 1,768 | $137K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 12,662 | $135K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 3,607 | $125K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 24,968 | $124K |
| X0616 | 1.0% | 624 | $120K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 963 | $74K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 590 | $68K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,644 | $52K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 572 | $52K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 258 | $52K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 409 | $44K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,683 | $39K |
| 80050 | General health panel | <1% | 903 | $37K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 609 | $36K |
| 97161 | <1% | 526 | $35K | |
| S9083 | Global fee urgent care centers | <1% | 324 | $35K |
| 80061 | Lipid panel | <1% | 2,418 | $32K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 879 | $31K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 229 | $31K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 762 | $29K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,301 | $28K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,127 | $26K |
| 83690 | <1% | 5,333 | $23K | |
| 97162 | <1% | 346 | $22K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 1,525 | $21K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 80 | $20K |
| 87070 | <1% | 2,815 | $20K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,511 | $20K |
| 84484 | <1% | 2,790 | $19K | |
| 87631 | <1% | 164 | $18K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 585 | $18K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 70 | $18K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 213 | $15K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 201 | $15K |
| 76642 | <1% | 334 | $14K | |
| 70496 | <1% | 74 | $14K | |
| 70498 | <1% | 73 | $14K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 277 | $12K |
| 80076 | <1% | 1,558 | $12K | |
| 93971 | <1% | 177 | $12K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,520 | $11K |
| 77066 | Tomosynthesis, mammo | <1% | 120 | $10K |
| 84703 | <1% | 1,055 | $10K | |
| 81001 | <1% | 3,934 | $10K | |
| 73564 | <1% | 476 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 279 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 356 | $9K |
| 86003 | <1% | 45 | $9K | |
| 71250 | <1% | 146 | $9K | |
| 73610 | <1% | 498 | $9K | |
| 83880 | <1% | 326 | $9K | |
| 84702 | <1% | 523 | $9K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 878 | $8K |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,252 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 86 | $7K |
| 83735 | <1% | 1,138 | $7K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 36 | $7K |
| 73030 | <1% | 463 | $7K | |
| 86803 | <1% | 350 | $6K | |
| 86618 | <1% | 271 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 285 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 286 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,518 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 913 | $6K |
| 83970 | <1% | 170 | $6K | |
| 82728 | <1% | 485 | $5K | |
| 74183 | <1% | 12 | $5K | |
| 76770 | <1% | 117 | $5K | |
| 85027 | <1% | 716 | $5K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 254 | $5K |
| 73630 | <1% | 441 | $5K | |
| 87040 | <1% | 231 | $5K | |
| 85610 | <1% | 1,323 | $4K | |
| 83605 | <1% | 652 | $4K | |
| 84153 | <1% | 190 | $4K | |
| 85379 | <1% | 450 | $4K | |
| 96367 | <1% | 174 | $4K | |
| 73562 | <1% | 263 | $4K | |
| 73110 | <1% | 311 | $4K | |
| 85730 | <1% | 652 | $4K | |
| 83540 | <1% | 452 | $4K | |
| 84439 | <1% | 474 | $4K | |
| 82607 | <1% | 270 | $3K | |
| 72100 | <1% | 161 | $3K | |
| 73130 | <1% | 300 | $3K | |
| 81003 | <1% | 1,162 | $3K | |
| 82570 | <1% | 473 | $3K | |
| 73502 | <1% | 168 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,264 | $3K |
| 73560 | <1% | 175 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 151 | $2K |
| 82805 | <1% | 81 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 937 | $2K |
| 94729 | <1% | 86 | $2K | |
| 82043 | <1% | 305 | $2K | |
| 90715 | <1% | 144 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 42 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 86 | $2K |
| 86038 | <1% | 134 | $2K | |
| 80081 | <1% | 25 | $2K | |
| 87186 | <1% | 267 | $2K | |
| 82784 | <1% | 107 | $2K | |
| 83550 | <1% | 398 | $2K | |
| 87077 | <1% | 265 | $2K | |
| 73590 | <1% | 112 | $2K | |
| 72110 | <1% | 87 | $2K | |
| 97165 | <1% | 24 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 143 | $2K |
| 88342 | <1% | 44 | $2K | |
| OP250 | <1% | 1,049 | $2K | |
| 86850 | <1% | 230 | $2K | |
| 78264 | <1% | 14 | $1K | |
| 94727 | <1% | 74 | $1K | |
| 84100 | <1% | 259 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,793 | $1K |
| 86901 | <1% | 342 | $1K | |
| 81002 | <1% | 397 | $1K | |
| 73080 | <1% | 118 | $1K | |
| 86900 | <1% | 342 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,039 | $1K |
| 87340 | <1% | 85 | $1K | |
| 86140 | <1% | 387 | $1K | |
| 96415 | <1% | 51 | $1K | |
| 74018 | <1% | 76 | $992.75 | |
| 87147 | <1% | 299 | $977.53 | |
| 85652 | <1% | 324 | $888.14 | |
| 82746 | <1% | 73 | $883.21 | |
| 85007 | <1% | 219 | $859.95 | |
| 77065 | Tomosynthesis, mammo | <1% | 12 | $858.01 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,302 | $849.13 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 446 | $831.68 |
| 82785 | <1% | 43 | $818.65 | |
| 82948 | <1% | 521 | $814.82 | |
| 86480 | <1% | 13 | $807.16 | |
| 86592 | <1% | 200 | $781.12 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 95 | $773.90 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 15 | $773.40 |
| 84145 | <1% | 47 | $738.72 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,007 | $576.63 |
| 81025 | <1% | 314 | $553.41 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 88 | $552.10 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $535.50 |
| 87430 | <1% | 76 | $478.80 | |
| 73140 | <1% | 56 | $475.88 | |
| 84156 | <1% | 132 | $459.39 | |
| 86255 | <1% | 29 | $454.08 | |
| 86235 | <1% | 12 | $444.73 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 797 | $431.55 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $408.51 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,353 | $401.75 |
| 94060 | <1% | 43 | $400.19 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 589 | $389.23 |
| 82950 | <1% | 51 | $348.50 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 12 | $336.84 |
| 82550 | <1% | 48 | $336.39 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,386 | $309.02 |
| 84550 | <1% | 56 | $303.65 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 137 | $298.01 |
| 84481 | <1% | 13 | $289.34 | |
| 300 | Patient transfer system <300 | <1% | 25 | $288.33 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 463 | $262.85 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 161 | $239.40 |
| 86430 | <1% | 40 | $236.22 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,479 | $211.67 |
| 86706 | <1% | 13 | $178.45 | |
| 95816 | <1% | 12 | $121.79 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 943 | $112.98 |
| 86704 | <1% | 12 | $111.26 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 234 | $105.78 |
| 82247 | <1% | 14 | $93.84 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,378 | $90.38 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 531 | $80.83 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16 | $77.33 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 37 | $53.45 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 786 | $16.46 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 323 | $6.56 |
| J3490 | Unclassified drugs | <1% | 130 | $1.20 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 126 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 38 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 17 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 45 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 38 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 27 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 44 | $0.00 |
| A9270 | Non-covered item or service | 0% | 144 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 102 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFE, SCOTT (VP FINANCE)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.